Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma (NHL) confirmed by centralized histological review. Patients received 28‐d cycles of 85 mg/m(2) pixantrone dimalea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettengell, Ruth, Sebban, Catherine, Zinzani, Pier Luigi, Derigs, Hans Gunter, Kravchenko, Sergey, Singer, Jack W., Theocharous, Panteli, Wang, Lixia, Pavlyuk, Mariya, Makhloufi, Kahina M., Coiffier, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074333/
https://www.ncbi.nlm.nih.gov/pubmed/27118109
http://dx.doi.org/10.1111/bjh.14101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074333/
https://www.ncbi.nlm.nih.gov/pubmed/27118109
http://dx.doi.org/10.1111/bjh.14101

Ejemplares similares